Trial Information

Summary: Asthma Study CIGE025A2432

Novartis is conducting this clinical trial to find out if the drug omalizumab (XolairŽ) has beneficial effects on the airways in people who have moderate to severe allergic asthma. XolairŽ has been approved in the European Union and by the U.S Food and Drug Administration for the treatment of persistent allergic asthma.

Post-marketing studies to delineate additional information including the drugs risks, benefits, and optimal use.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 27, 2008 at 1:00:43 PM